Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Robert G. Schaub"'
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 5085, p 5085 (2020)
International Journal of Molecular Sciences
Volume 21
Issue 14
International Journal of Molecular Sciences
Volume 21
Issue 14
Invariant natural killer T (iNKT) cells are innate-like T lymphocytes characterized by the expression of an invariant T cell receptor (iTCR) that recognizes glycolipid antigens presented by the MHC I-like CD1d molecule. Following antigenic stimulatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00936c25e35aea6e06a808255facfd59
https://www.mdpi.com/1422-0067/21/14/5085
https://www.mdpi.com/1422-0067/21/14/5085
Autor:
Patrick A Lester, Karen J. Roelofs, Angela Pechota, Nichole K. Doornbos, Frank J. Londy, Peter K. Henke, Shirley K. Wrobleski, Thomas W. Wakefield, Joy E. Gabriel, Garrett Reynolds, Suzan E. Lowe, Daniel D. Myers, Jose A. Diaz, Angela E. Hawley, Robert G. Schaub
Publikováno v:
Journal of vascular surgery. Venous and lymphatic disorders. 2(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd7ca773c6e8d7856df66dbe513e83f3
https://pubmed.ncbi.nlm.nih.gov/26993008
https://pubmed.ncbi.nlm.nih.gov/26993008
Autor:
Leonid A. Parunov, Kathleen E. McGinness, Mikhail A. Panteleev, Natalia P. Soshitova, Fazoil I. Ataullakhanov, Konstantin G. Kopylov, James C. Gilbert, Robert G. Schaub, Maria A. Kumskova, Anna N. Balandina, Olga A. Fadeeva
Publikováno v:
Journal of Thrombosis and Haemostasis. 9:1825-1834
Summary. Background: Tissue factor pathway inhibitor (TFPI) is a major regulator of clotting initiation and a promising target for pro- and anticoagulation therapy. The aptamer BAX499 (formerly ARC19499) is a high-affinity specific TFPI antagonist de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8cc8cdda05705fac5a0de77dd1576e
https://doi.org/10.1111/j.1538-7836.2011.04412.x
https://doi.org/10.1111/j.1538-7836.2011.04412.x
Autor:
Robert G. Schaub
Publikováno v:
Biochemical Pharmacology. 82:91-98
Hemophilia is a family of rare bleeding disorders. The two primary types, hemophilia A and hemophilia B, are caused by recessive X-chromosome linked mutations that result in deficiency of coagulation factor VIII (FVIII) or factor IX (FIX), respective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70d71f4fb8b50ec0f3587121ee04202c
https://doi.org/10.1016/j.bcp.2011.03.015
https://doi.org/10.1016/j.bcp.2011.03.015
Autor:
Gregory Ducrocq, Jean-François Théorêt, Firas Dandachli, Mark Y. Chan, James C. Gilbert, Dabit Arzamendi, Yahye Merhi, Robert G. Schaub, Jean-François Tanguay, Walid Mourad
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 17:E70-E78
The von Willebrand factor (vWF) aptamer, ARC1779 that blocks the binding of vWF A1-domain to platelet glycoprotein 1b (GPIb) at high shear, may deliver a site-specific antithrombotic effect. We investigated the efficiency of ARC1779 on platelet funct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b2f0bf7cb164ebb5c9f767ed2d81926
https://doi.org/10.1177/1076029610384114
https://doi.org/10.1177/1076029610384114
Autor:
Steve Tam, Qin Wang, Adrian Huang, Desiree H.H. Tsao, Natalia Sushkova, Michael Dennis Lowe, Gray D. Shaw, Patricia W. Bedard, Li Di, Boris Tchernychev, James C. Keith, Neelu Kaila, Robert G. Schaub, Kristin Janz, Valerie Clerin, Alessandro Moretto
Publikováno v:
Journal of Medicinal Chemistry. 53:6003-6017
Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::037abec3fb0ac922950e891045ae2fb2
https://doi.org/10.1021/jm9013696
https://doi.org/10.1021/jm9013696
Autor:
Robert G. Schaub, K. Barry Deatrick, John E. Rectenwald, Shirley K. Wrobleski, Daniel D. Myers, Eduardo Ramacciotti, Thomas W. Wakefield, Frank J. Londy, Peter K. Henke
Publikováno v:
Thrombosis Research. 125:e138-e142
P-selectin antagonism has been shown to decrease thrombogenesis and inflammation in animal models of deep venous thrombosis (DVT).To determine the effectiveness of P-selectin inhibitors versus saline and enoxaparin in venous thrombus resolution in no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68248e65be16d01a49c2f070efca3319
https://doi.org/10.1016/j.thromres.2009.10.022
https://doi.org/10.1016/j.thromres.2009.10.022
Autor:
Paul Knöbl, Florian B. Mayr, Petra Jilma-Stohlawetz, Patricia G Wagner, James C. Gilbert, Robert G. Schaub, Jolanta M. Siller-Matula, Bernd Jilma
Publikováno v:
Transfusion. 50:1079-1087
Background In thrombotic thrombocytopenic purpura (TTP), ultralarge von Willebrand factor (VWF) multimers bind platelet (PLT) glycoprotein Ib and lead to the formation of disseminated fibrin-poor, VWF-rich PLT thrombi. The aptamer ARC1779 blocks bind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::437e38794ddc8ba0bf4d2696ca5165a8
https://doi.org/10.1111/j.1537-2995.2009.02554.x
https://doi.org/10.1111/j.1537-2995.2009.02554.x
Autor:
Frank J. Londy, Shirley K. Wrobleski, Neelu Kaila, Paul J. Zajkowski, Patricia W. Bedard, Nicole E. Ballard, Daniel D. Myers, George P. Vlasuk, Robert G. Schaub, Angela E. Hawley, Thomas R. Meier, Thomas W. Wakefield
Publikováno v:
Thrombosis and Haemostasis. 99:343-351
SummaryP-selectin inhibition has been evaluated as a therapeutic for prevention and treatment of venous thrombosis. In this study, a novel oral small-molecule inhibitor of P-selectin, PSI-421, was evaluated in a baboon model of stasis induced deep ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::291955eaf2d3703645f84049fe6aa265
https://doi.org/10.1160/th07-10-0608
https://doi.org/10.1160/th07-10-0608
Autor:
Thomas V. Holohan, Christopher J. Horvath, Tia DeFeo-Fraulini, H. Nicholas Marsh, Robert G. Schaub, Sleiman BouFakhreddine, James C. Gilbert, Judith M. Healy, Renta Hutabarat, Patricia G. Merlino
Publikováno v:
Circulation. 116:2678-2686
Background— ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87c290da4be7e22fd6f1cdee69273417
https://doi.org/10.1161/circulationaha.107.724864
https://doi.org/10.1161/circulationaha.107.724864